Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung cancer

BACKGROUND: Preclinical data indicate EGFR signals through both kinase-dependent and independent pathways and that combining a small-molecule EGFR inhibitor, EGFR antibody, and/or anti-angiogenic agent is synergistic in animal models. METHODS: We conducted a dose-escalation, phase I study combining...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Falchook, Gerald S., Naing, Aung, Hong, David S., Zinner, Ralph, Fu, Siqing, Piha-Paul, Sarina A., Tsimberidou, Apostolia M., Morgan-Linnell, Sonia K., Jiang, Yunfang, Bastida, Christel, Wheler, Jennifer J., Kurzrock, Razelle
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2013
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3702212/
https://ncbi.nlm.nih.gov/pubmed/23435217
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares